Clinical manifestations and prognosis of giant cell arteritis: A retrospective cohort study

The aim of the study was to evaluate the clinical manifestations and survival of patients with giant cell arteritis (GCA).

Methods. A retrospective study included 166 patients with newly diagnosed GCA. Clinical, laboratory and instrumental data, three sets of classification criteria were used to confirm the diagnosis: the American College of Rheumatology (ACR) 1990, the revised ACR criteria of 2016 and/or the new ACR and European Alliance of Associations for Rheumatology (EULAR) 2022 criteria. Some of the patients underwent instrumental investigations: temporal artery ultrasound Doppler (n=61), contrast-enhanced computed tomography (CT) (n=5), CT angiography (n=6), magnetic resonance imaging (n=4), magnetic resonance angiography (n=3) and 18F-FDG positron emission tomography/CT (n=47). Overall and recurrence-free survival were analyzed using survival tables, Kaplan – Meier method.

Results. The most frequent first manifestations of GCA were headache (81.8%), weakness (64%), fever (63.8%) and symptoms of rheumatic polymyalgia (56.6%). Changes of temporal arteries in color duplex scanning were detected in 44 out of 61 patients. GCs therapy was performed in all patients who agreed to be treated (n=158), methotrexate was used in 49 out of 158 patients, leflunomide – in 9 patients. In 45 (28.5%) out of 158 patients a stable remission was achieved as a result of GCs monotherapy, in 120 (75.9%) patients long-term maintenance therapy with GCs was required to prevent exacerbations, including 71 (44.9%) patients – in combination with methotrexate or other immunosuppressive drugs. The follow-up period of patients with a history of relapses was 21.0 (8.0–54.0) months. Relapses developed in 73 (46.2%) patients. The overall one-year survival rate was 97.1% [95% confidence interval (CI): 94.3; 99.9], and the five-year survival rate of patients was 94.6% [95% CI: 90.2; 99.0]. The one-year relapse-free survival rate was 86.4% [95% CI: 80.5; 92.3], and the five-year relapse-free survival rate was 52.4% [95% CI: 42.0; 62.8]. 12 (7.2%) of 166 patients died. The cause of death was myocardial infarction in two patients, stroke in two patients, and breast cancer in one patient; in the remaining seven cases, the cause of death was not determined.

Conclusion. Given the high frequency of disease exacerbation, patients with GCA require long-term follow-up, especially during the first year after diagnosis.

1. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016;315(22):2442-2458. doi: 10.1001/jama.2016.5444

2. Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003;349(2):160-169. doi: 10.1056/NEJMra022694

3. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50-57. doi: 10.1056/NEJMcp1214825

4. Meshkov AD, Novikov PI, Fomin VV, Moiseev SV. Giant cell arteritis: Diagnostic and treatment. Clinical Pharmacology and Therapy. 2014;23(2):48-54 (In Russ.).

5. Satybaldyev AM. Giant cell arteritis. Part I. Terminology, classification, clinical manifestations, diagnosis. Modern Rheumatology Journal. 2012;(3):23-27 (In Russ.). doi: 14412/1996-7012-2012-741

6. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48:73-75. doi: 10.1016/j.jaut.2014.01.017

7. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-639. doi: 10.1002/art.30155

8. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: Revisiting the concept of the disease. Rheumatology. 2017;56(4):506-515. doi: 1093/rheumatology/kew273

9. Wigley RD, Zhang NZ, Zeng QY, Shi CS, Hu DW, Couchman K, et al. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. J Rheumatol. 1994;21(8):1484-1490.

10. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum Off J Am Coll Rheumatol. 1983;26(10):1214-1219. doi: 10.1002/art.1780261007

11. Meshkov AD, Maslyansky AL, Tkacheva ON, Mazurov VI. Treatment of giant cell arteritis: Current possibilities and prospects of steroid-sparing therapy. Therapy. 2023;1(9):78-88 (In Russ.). doi: 10.18565/therapy.2023.1.78-88

12. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550-555. doi: 10.1016/s0161-6420(93)31608-8

13. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: Diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32(3):259. doi: 10.1097/WNO.0b013e318268aa9b

14. Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57(2):322-328. doi: 10.1093/rheumatology/kex397

15. Mukhin NA, Meshkov AD, Novikov PI, Moiseev SV, Scherbakova VD, Manukova VA, et al. Giant cell arteritis: Clinical manifestations and methods of early diagnosis. Clinical Pharmacology and Therapy. 2015;24(3):79-85 (In Russ.).

16. de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, Aouba A. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol. 2019;37(Suppl 117(2)):57-60.

17. Gajree S, Borooah S, Dhillon N, Goudie C, Smith C, Aspinall P, et al. Temporal artery biopsies in south-east Scotland: A five year review. J R Coll Physicians Edinb. 2017;47(2):124-128. doi: 10.4997/JRCPE.2017.203

18. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-606. doi: 10.1007/s10157-013-0869-6

19. Novikov PI, Semenkova EN, Moiseev SV. Modern nomenclature of systemic vasculitis. Clinical Pharmacology and Therapy. 2013;22(1):70-74 (In Russ.).

20. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989-1994. doi: 10.1136/annrheumdis-2012-202408

21. Breuer GS, Poltorak V, Nesher G. Survival of patients with giant cell arteritis: A controversial issue. Clin Exp Rheumatol. 2020;38(Suppl 124):210-213.

22. Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: A multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016;68(6):1477-1482. doi: 10.1002/art.39596

23. Mollan SP, Begaj I, Mackie S, O’Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002–13, without a decrease in associated sight loss: Potential implications for service provision. Rheumatology. 2015;54(2):375-377. doi: 10.1093/rheumatology/keu433

24. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi: 10.1002/art.1780330810

25. Salehi-Abari I. 2016 ACR revised criteria for early diagnosis of giant cell (temporal) arteritis. Autoimmune Dis Ther Approaches Open Access. 2016;3:1-4.

26. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647-1653. doi: 10.1136/ard-2022-223480

27. Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/ American College of Rheumatology collaborative initiative. 2012;64:943-954. doi: 10.1002/art.34356

28. Bland JM, Altman DG. Survival probabilities (the Kaplan – Meier method). BMJ. 1998;317:1572-1580. doi: 10.1136/bmj.317.7172.1572

29. Majerovich K, Junek M, Khalidi N, Garner S. Duration of steroid therapy and temporal artery biopsy positivity in giant cell arteritis: A retrospective cohort study. J Rheumatol. 2023;50(7):965-966. doi: 10.3899/jrheum.220860

30. Dagostin MA, Pereira RMR. Giant cell arteritis: Current advances in pathogenesis and treatment. Rijeka:IntechOpen;2020. doi: 10.5772/intechopen.91018

31. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381(9860):63-72. doi: 10.1016/S0140-6736(12)60680-1

32. Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: Results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S103-S106.

33. Ninet JP, Bachet P, Dumontet CM, Du Colombier PB, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med. 1990;88(1):13-20. doi: 10.1016/0002-9343(90)90121-s

34. Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, et al. Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmun Rev. 2015;14(4):352-357. doi: 10.1016/j.autrev.2014.12.005

35. Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194-201. doi: 10.1097/MD.0000000000000033

36. Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154(4):722-729. doi: 10.1016/j.ajo.2012.03.045

37. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-1597. doi: 10.1093/rheumatology/keq039a

38. Moiseev SV, Smitienko I, Bulanov N, Novikov PI. The role of temporal artery biopsy in patients with giant-cell arteritis is debated. Ann Rheum Dis. 2019;78(4):e31. doi: 10.1136/annrheumdis-2018-213282

39. Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology. 2017;56(9):1479-1483. doi: 10.1093/rheumatology/kex143

40. Filatova EE, Bulanov NM, Meshkov AD, Borodin OO, Smitienko IO, Chachilo EV, et al. Damage to extracranial arteries in giant cell arteritis according to PET/CT. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1):106-111 (In Russ.). doi: 10.47360/1995-4484-2023-106-111

41. Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica – A prospective study of 99 patients. Rheumatology. 2018;57(11):1908-1916. doi: 10.1093/rheumatology/kex376

42. de Boysson H, Lambert M, Liozon E, Boutemy J, Maigné G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016;95(26):e3818. doi: 10.1097/MD.0000000000003818

43. Malich L, Gühne F, Hoffmann T, Malich A, Weise T, Oelzner P, et al. Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis. RMD Open. 2022;8(2):e002464. doi: 10.1136/rmdopen-2022-002464

44. Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken). 2020;72(11):1615-1624. doi: 10.1002/acr.24055

45. Förster S, Tato F, Weiss M, Czihal M, Rominger A, Bartenstein P, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa. 2011;40(3):219-227. doi: 10.1024/0301-1526/a000096

46. Nielsen BD, Hansen IT, Kramer S, Haraldsen A, Hjorthaug K, Bogsrud TV, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: A case-control study. Eur J Nucl Med Mol Imaging. 2019;46(1):184-193. doi: 10.1007/s00259-018-4106-0

47. Rottenburger C, Mensch N, Imfeld S, Aschwanden M, Glatz K, Staub D, et al. 18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches. Swiss Med Wkly. 2021;151:w20512. doi: 10.4414/smw.2021.20512

48. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672

49. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi: 10.1002/art.41774

50. Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities. Nat Rev Rheumatol. 2017;13(10):578-592. doi: 10.1038/nrrheum.2017.142

51. Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213-1217. doi: 10.3899/jrheum.141347

52. Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023:ard-2022-223429. doi: 10.1136/ard-2022-223429

53. Lavergne A, Dumont A, Deshayes S, Boutemy J, Maigné G, Silva NM, et al. Efficacy and tolerance of methotrexate in a reallife monocentric cohort of patients with giant cell arteritis. Semin Arthritis Rheum. 2023;60:152192. doi: 10.1016/j.semarthrit.2023.152192

54. Dumont A, Parienti JJ, Delmas C, Boutemy J, Maigné G, Martin Silva N, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol. 2020;47(1):108-116. doi: 10.3899/jrheum.181127

55. Vautier M, Dupont A, de Boysson H, Comarmond C, Mirault T, Mekinian A, et al. Prognosis of large vessel involvement in large vessel vasculitis. J Autoimmun. 2020;108:102419. doi: 10.1016/j.jaut.2020.102419

56. Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, et al. Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken). 2017;69(3):430-438. doi: 10.1002/acr.22942

57. Garen T, Lerang K, Hoffmann-Vold AM, Andersson H, Midtvedt Ø, Brunborg C, et al. Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology (Oxford). 2019;58(2):313-320. doi: 10.1093/rheumatology/key285

58. Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, Lester S. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513-519. doi: 10.1016/j.semarthrit.2016.08.015